Joint Statement of Health Groups against the Trans-Pacific Partnership Agreement (TPPA)
Online Publication Date: 18 April 2013
THE TRANS-PACIFIC PARTNERSHIP AGREEMENT (TPPA)
medicines save lives by preventing, curing and managing non-communicable and communicable
diseases for all Malaysians, especially the lower-income and marginalised
United States via the Trans-Pacific Partnership Agreement (TPPA) is demanding
strict provisions that will reduce access to these affordable medicines. We oppose
the following provisions because deprivation of affordable medicines will
result in increased burden of disease, increased morbidity, and indirectly,
productivity and human resources losses that will affect the economy of the
nation. This economic and social burden will lie on the government – when
medicines are expensive, people will eventually run out of money and turn to
government hospitals for treatment.
of non-communicable diseases and communicable diseases alike require affordable
generic medicines and affordable technology, and we categorically oppose US
demands for longer and stronger patents on medicines and medical technologies
that are essential to save Malaysian lives.
most frequent occurring cancer is breast cancer, which similarly to other
cancers, requires affordable chemotherapy medicines. HIV second line medicines
like Kaletra are required to save lives, and are often out of reach of the
pockets of persons living with HIV. Many other conditions depend on generic
medicines: cancer, tuberculosis, and malaria are just a few. According to the
2011 National Health and Morbidity Survey, 2.6 million Malaysians are diabetic.
80% of these people attend government clinics and hospitals, meaning that a
majority of them take generic medicines.
medicines are very expensive:
Glivec, the gastrointestinal cancer medicine, is RM 10,000 per month
Sorafenib Tosylate, the medicine to treat liver and kidney cancer, is RM 9865
per person per month, whereas the generic version can cost RM 370-RM 501
(US$116-$157) per person per month because the company holding the patent has
the exclusive right to make or import that medicine for a 20-year period. The
US wants to extend this period. This means that Malaysians will be denied access
to cheaper generic versions of medicines for extra years.
addition to that, the US wants Malaysian negotiators to agree to new kinds of
patents. Patents are normally granted on the medicine itself, but the US wants
to patent the way to use a medicine, for example, if a medicine is found to
treat another disease, that medicine is now eligible for a second patent. The
US also wants to patent new forms of a medicine, eg changing the medicine from
a tablet to asyrup (so that children can take it) and according to the new
patent rules, the medicine could have a new 20-year patent. The US is also
demanding strict border control measures which enable TPP governments to seize
generic medicines when being imported, exported or in transit, so long as they
look confusingly similar to trademarked goods.
of these are tricks to ensure that Malaysians are forced to use expensive
patented medicines for longer periods of time, so US-based innovators of
medicine earn more profits.
stand in opposition to any and all proposals that negatively affect access to
medicines in the Trans-Pacific Partnership Agreement including:
EXPANSIVE PATENT PROTECTION for new forms, uses and methods of using known
These aggressive low patenting standards can extend pharmaceutical monopolies
variations on old products, including those that contribute nothing to
PATENT TERM EXTENSIONS that stretch the duration of a patent beyond 20 years.
PATENT LINKAGE that prevents registration of generic medicines and facilitates
ELIMINATING SAFEGUARDS against patent abuse, such as pre-grant opposition.
Pre-grant opposition allows any party to oppose the grant of a patent.
BIASED PROCEDURAL REQUIREMENTS that presume challenged patents valid and
measure damages by the patent holder’s assessment of value.
DATA EXCLUSIVITY that prevents health authorities from relying on clinical
trial data to register generic versions of medicines.
BORDER MEASURES that could lead to unjustified seizures of generic medicines.
INVESTMENT RULES that could allow multinational companies to sue governments
over application of domestic health regulations in private international
the negotiations and texts are secret, Malaysians have no way of knowing what
has been agreed to and whether there have been overt and arbitrary breaches of
the right to health. What we know so far in regard to medicines has been
gathered from leaked documents from the negotiations which can be found at:
ask that the Malaysian government reject patent extension provisions, data
linkage, and border control measures that enable foreign customs officials to
seize our medicines, and all other proposals as above that negatively affect
access to medicines.
stand in solidarity with all other peoples & movements whose rights to
life, health, livelihood, equality, equity, food, environment, knowledge,
traditional systems of life & livelihood will also be negatively impacted
by these free trade agreements that threaten to widen the gap between the rich
& the poor not only between countries but within countries as well.
Datuk Dr Raj Karim
Malaysian AIDS Council
Chief Executive Officer
Breast Cancer Welfare Association
National Cancer Society Malaysia
Prof. Dr. Roslina Abdul Manap
Malaysian Thoracic Society
Dato’ Faridah Khalid
National Council of Women’s Organisations
Sabah AIDS Support Services Association
Syaiful Fazlie Zakaria
Persatuan Cahaya Harapan Negeri Kedah
Acting Executive Director
The Estates Hospital Asisstants Association
Dr. Suresh Kumarasamy
Obstetrical & Gynaecological Society of
Fann Peng Tong
Pertubuhan Kebajikan Intan Zon Kehidupan
Dr. Zaiton Yahya
Sandakan AIDS Support Group Association
Zairil Khir Johari
Chief Executive Officer
Abdullah Sani B. Md Yusoff
Kelab Sahabat Meta Tampin
Dr. H. Krishna Kumar
Honorary General Secretary
Malaysian Medical Association
Lim Beng Poh, PPN, PJK
Penang Family Health Development
Hafidzan Md Salleh
Kelab Rakan Melaka